Bariatric Arterial Embolization for Obesity: A Review of Early Clinical Evidence
- 298 Downloads
Obesity is a worldwide public health epidemic that leads to increased morbidity, mortality, and cost burden to health care. Although bariatric surgery has been recognized as a standard invasive treatment for obesity, it is accompanied by relatively high morbidity and cost burden, as well as limited treatment outcome. Therefore, alternative treatments with lower morbidity and cost for surgery that target patients who are obese, but not morbidly obese, are needed. A minimally invasive trans-catheter procedure, named bariatric arterial embolization or bariatric embolization (BAE), has been identified as a potential solution, based on its safety and preliminary efficacy profiles. The purpose of this review is to introduce up-to-date clinical data and discuss future directions for BAE for the treatment of obesity.
KeywordsObesity Bariatric Embolization Left gastric artery Weight loss
Dr. Weiss is funded through NIH/NIBIB R01EB017615, NIH/NIBIB T32EB006351, SIR Foundation (FSDG), Siemens Healthcare, BTG, Merit Medical, and Medtronic. Dr. Zhong receives funding through Fundamental Research Funds for the Central Universities, and the Scientific Research Innovation Program for College and University Graduates of Jiangsu Province (KYZZ16_0133). Funding sources have had no involvement in the financial support for the preparation of this article.
Compliance with Ethical Standards
Conflict of interest
Dr. Weiss is a consultant for Medtronic and BTG.
- 4.Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67. https://doi.org/10.1016/s0140-6736(10)62037-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Vix M, Liu KH, Diana M, D’Urso A, Mutter D, Marescaux J. Impact of Roux-en-Y gastric bypass versus sleeve gastrectomy on vitamin D metabolism: short-term results from a prospective randomized clinical trial. Surg Endosc. 2014;28(3):821–6. https://doi.org/10.1007/s00464-013-3276-x.CrossRefPubMedGoogle Scholar
- 11.Clinical Guidelines on the Identification. Evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obesity research. 1998;6(Suppl 2):51S–209S.Google Scholar
- 17.Encinosa WE, Bernard DM, Chen CC, Steiner CA. Healthcare utilization and outcomes after bariatric surgery. Med Care. 2006;44(8):706–12. https://doi.org/10.1097/01.mlr.0000220833.89050.ed.CrossRefPubMedGoogle Scholar
- 18.Keating C, Neovius M, Sjoholm K, Peltonen M, Narbro K, Eriksson JK, et al. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. Lancet Diabet Endocrinol. 2015;3(11):855–65. https://doi.org/10.1016/S2213-8587(15)00290-9.CrossRefGoogle Scholar
- 19.Weiner JP, Goodwin SM, Chang HY, Bolen SD, Richards TM, Johns RA, et al. Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. JAMA Surg. 2013;148(6):555–62. https://doi.org/10.1001/jamasurg.2013.1504.CrossRefPubMedGoogle Scholar
- 22.Maahs D, de Serna DG, Kolotkin RL, Ralston S, Sandate J, Qualls C, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2006;12(1):18–28. https://doi.org/10.4158/EP.12.1.18.CrossRefGoogle Scholar
- 24.Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52. https://doi.org/10.1016/S0140-6736(11)60205-5.CrossRefPubMedGoogle Scholar
- 38.Arepally A, Barnett BP, Patel TH, Howland V, Boston RC, Kraitchman DL, et al. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology. 2008;249(1):127–33. https://doi.org/10.1148/radiol.2491071232.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Paxton BE, Arepally A, Alley CL, Kim CY. Bariatric embolization: pilot study on the impact of gastroprotective agents and arterial distribution on ulceration risk and efficacy in a porcine model. J Vasc Interv Radiol. 2016;27(12):1923–8. https://doi.org/10.1016/j.jvir.2016.07.021.CrossRefPubMedGoogle Scholar
- 45.Diana M, Pop R, Beaujeux R, Dallemagne B, Halvax P, Schlagowski I, et al. Embolization of arterial gastric supply in obesity (EMBARGO): an endovascular approach in the management of morbid obesity. proof of the concept in the porcine model. Obes Surg. 2015;25(3):550–8. https://doi.org/10.1007/s11695-014-1535-0.CrossRefPubMedGoogle Scholar
- 49.Syed MI, Morar K, Shaikh A, Craig P, Khan O, Patel S, et al. Gastric artery embolization trial for the lessening of appetite nonsurgically (GET LEAN): six-month preliminary data. Journal of vascular and interventional radiology: JVIR. 2016;27(10):1502–8. https://doi.org/10.1016/j.jvir.2016.07.010.CrossRefPubMedGoogle Scholar